NVIDIA
NVDA
Tesla
TSLA
Taiwan Semiconductor
TSM
4
Palantir
PLTR
5
Advanced Micro Devices
AMD
US Stock MarketDetailed Quotes
DCTH Delcath Systems
- 13.730
- +0.380+2.85%
Trading Mar 4 13:34 ET
497.03MMarket Cap-11.74P/E (TTM)
13.730High12.620Low312.09KVolume13.040Open13.350Pre Close4.09MTurnover0.92%Turnover RatioLossP/E (Static)36.20MShares16.43052wk High57.93P/B464.48MFloat Cap2.25052wk Low--Dividend TTM33.83MShs Float7069.999Historical High--Div YieldTTM8.32%Amplitude-9223372036.855Historical Low13.101Avg Price1Lot Size
About Delcath Systems Company
Delcath Systems, Inc. is an oncology company, which engages in the treatment of primary and metastatic liver cancers. Its products include CHEMOSAT and HEPZATO. The company was founded in August 1988 and is headquartered in Queensbury, NY.
Company Profile
SymbolDCTH
Company NameDelcath Systems
Issue Price10.00
Founded1988
CEOMr. Gerard J. Michel
MarketNASDAQ
Employees76
Fiscal Year Ends12-31
Address566 Queensbury Avenue
CityQueensbury
ProvinceNew York
CountryUnited States of America
Zip Code12804
Phone1-212-489-2100
Websitehttp://www.delcath.com
Company Executives
- Name
- Position
- Salary
- Gerard J. Michel
- Interim Principal Accounting Officer, Director, President and Chief Executive Officer
- 2.52M
- Dr. Martha S. Rook, PhD
- Chief Operating Officer
- --
- David L. Hoffman
- General Counsel, Chief Compliance Officer and Corporate Secretary
- --
- Kevin Muir
- General Manager, Interventional Oncology
- 1.02M
- Dr. Johnny John, M.D.
- Senior Vice President, Clinical Development and Medical Affairs
- --
- Sandra Pennell
- Senior Vice President, Finance
- --
- John Richard Sylvester
- Chairman of the Board
- 204.88K
- Dr. Roger G. Stoll,PhD
- Independent Director
- 188.48K
- Elizabeth A. Czerepak
- Independent Director
- 188.51K
- Steven Salamon
- Independent Director
- 183.96K
- Dr. Gilad Aharon, PhD
- Independent Director
- 172.96K